Lenti-2XPRE-GFP
(Plasmid
#206169)
-
PurposepMVP Gateway destination vector (3rd generation lentiviral vector) containing 2 consensus PGR binding sites upstream of a minimal 2YBTATA promoter
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 206169 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepMVP/Lenti/Neo-DEST
- Backbone size w/o insert (bp) 8462
- Total vector size (bp) 8304
-
Vector typeLentiviral
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert name2X PRE-eGFP
-
SpeciesH. sapiens (human), Synthetic; PRE is human PGR binding site, 2YBTATA is a synthetic minimal promotor, eGFP is a fluorescent protein derived from Jellyfish
-
Insert Size (bp)1466
- Promoter 2YBTATA
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer Attb1 fw
- 3′ sequencing primer hGH-PA-R (Common Sequencing Primers)
Resource Information
-
A portion of this plasmid was derived from a plasmid made byGateway plasmids used to make this vector: Addgene: #206166, #121730, #121746, #121850
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
Lenti-2XPRE-GFP was a gift from Renee van Amerongen (Addgene plasmid # 206169 ; http://n2t.net/addgene:206169 ; RRID:Addgene_206169) -
For your References section:
A molecular toolbox to study progesterone receptor signaling. Aarts MT, Wagner M, van der Wal T, van Boxtel AL, van Amerongen R. J Mammary Gland Biol Neoplasia. 2023 Nov 29;28(1):24. doi: 10.1007/s10911-023-09550-0. 10.1007/s10911-023-09550-0 PubMed 38019315